Washington, DC—Late-breaking research presented at the recent annual conference of the American College of Rheumatology and the Association of Rheumatology Health Professionals highlighted results from phase 2 and 3 clinical trials testing experimental agents to treat arthritis. Candidates ranged from the nonspecific anti-inflammatory chondroitin sulfate to biologic agents that target specific immune response modifiers.
For rheumatoid arthritis, a disease characterized by immune and/or inflammatory responses gone awry, researchers are testing the potential of a number of therapies that target immune response modifiers, such as cytokines and their cell receptors. An international team of investigators reported results from a randomized, double-blind, placebo-controlled phase 2a trial of a drug called CP-690,550, which inhibits a receptor for several interleukins and had shown efficacy in targeting this receptor (Janus kinase 3) in rodent models of arthritis and in humans with psoriasis.
Hampton T. Arthritis Clinical Trial Results Revealed. JAMA. 2007;297(1):28-29. doi:10.1001/jama.297.1.28